CASE CONTROL STUDY ABOUT THE RISK OF PANCREATIC CANCER WITH DIPEPTIDYL PEPTIDASE-4 INHIBITORS

• In: What’s new in practice? Part 1 on Tuesday, 24 September 2019, 11:20-11:30
• At: AbuDhabi (United Arab Emirates) (2019)
• Type: Presentation
• By: MANSOUR, Maryline (Lebanese International University, Pharmaceutical, Lebanon)
• Co-author(s): Maryline Hikmat Mansour: PharmD, Lebanese International University, Beirut, Lebanon
  Faten Awada: PharmD, Lebanese International University, Beirut, Lebanon
  Jihan Safwan: Biomedical Sciences Department , Lebanese International University, Beirut, Lebanon
  Nathalie Lahoud: PharmD, Lebanese International University, Beirut, Lebanon
  Faraj Saade: Biomedical Sciences Department, Lebanese International University, Beirut, Lebanon
  Michelle Cherfan: Biomedical Sciences Department, Lebanese International University, Beirut, Lebanon
  Marwan Akel: Pharmacy Practice, Lebanese International University, Beirut, Lebanon
  Fouad Sakr: PharmD, Lebanese International University, Beirut, Lebanon
  Mariam Dabbous: Pharmacy Practice, Lebanese International University, Beirut, Lebanon
  Mohamad Rahal: Pharmaceutical Sciences, Lebanese International University, Beirut, Lebanon
  
• Abstract:

  Background

  Pancreatic cancer is one of the deadliest malignancies worldwide. Since, the risk of this disease with incretin based therapies is controversial, we conducted this study to evaluate the risk of this type of cancer with dipeptidyl peptidase-4 (DPP-4) inhibitors.

  Methods

  A retrospective case-control study was conducted among Lebanese

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login